Effect of KMC on Neurobehavior of Preterm Neonates
Launched by AIN SHAMS UNIVERSITY · Nov 10, 2018
Trial Information
Current as of June 03, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Stable preterm neonates with gestational age between 31 and 35 weeks.
- Exclusion Criteria:
- • Neonates with major congenital birth defects or chromosomal anomalies.
- • Perinatal asphyxia and intra-ventricular hemorrhage.
- • Hemodynamically significant cardiac abnormalities.
- • Neonates received postnatal steroids.
- • Neonates whose mothers had a history of drug abuse during pregnancy.
About Ain Shams University
Ain Shams University, established in Cairo, Egypt, is a prestigious higher education institution renowned for its commitment to academic excellence and research innovation. As a clinical trial sponsor, the university leverages its extensive resources and expertise in various medical and scientific disciplines to advance healthcare through rigorous research initiatives. With a focus on ethical practices and adherence to regulatory standards, Ain Shams University aims to contribute to the development of new therapies and improve patient outcomes, fostering collaboration among researchers, healthcare professionals, and industry partners in the pursuit of medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials